Acceleron Pharma (XLRN) Misses Q4 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q4 EPS by 7c

Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

February 27, 2019 4:05 PM EST

- MEDALIST and BELIEVE Phase 3 trial presentations at the 60th American Society of Hematology (ASH) Annual Meeting both selected for Best of ASH -

- Luspatercept Biologics License Application (BLA) submission expected in April 2019 -

- Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) anticipated during 2019 -

- Pulmonary program on track with two Phase 2 trials of sotatercept in pulmonary arterial hypertension (PAH) currently active -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc.... More